Volume 17, Number 1—January 2011
Dispatch
Serotype Distribution and Drug Resistance in Streptococcus pneumoniae, Palestinian Territories
Randa Kattan, Amal Abu Rayyan, Inas Zheiman, Suzan Idkeidek, Sabri Baraghithi, Nabeel Rishmawi, Sultan Turkuman, Afaf Abu-Diab, Riyad Ghneim, Madeleine Zoughbi, Rula Dauodi, Raed Ghneim, Abed-El-Razeq Issa, Issa Siryani, Randa Al Qas, Rawan Liddawi, Hatem Khamash, Moein Kanaan, Hiyam Marzouqa, and Musa Y. Hindiyeh
Table A1
Distribution of Streptococcus pneumoniae serotypes and antimicrobial susceptibility patterns, Palestinian Territories, West Bank*
| Serotype | No. (%) isolates | Penicillin, % |
Cefotaxime, % |
Co-trimoxazole, % |
Erythromycin, % |
Ofloxacin, % |
Vancomycin, % |
|||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | S | I | R | S | I | R | S | I | R | S | I | R | |||||||
| 6A/B | 17 (14.2) | 100 | 0 | 0 | 100 | 0 | 0 | 52.9 | 11.8 | 35.3 | 47.1 | 5.9 | 47.1 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 14 | 16 (13.3) | 87.5 | 13.5 | 0 | 100 | 0 | 0 | 18.8 | 6.2 | 75 | 25 | 0 | 75 | 87.5 | 12.5 | 0 | 100 | 0 | 0 | |||||
| 1 | 14 (11.7) | 100 | 0 | 0 | 100 | 0 | 0 | 7.14 | 35.7 | 57.1 | 92.9 | 7.1 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 9V | 11 (9.2) | 100 | 0 | 0 | 100 | 0 | 0 | 27.3 | 18.2 | 54.6 | 90.9 | 0 | 9.1 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 5 | 9 (7.5) | 100 | 0 | 0 | 100 | 0 | 0 | 11.1 | 66.7 | 22.2 | 88.9 | 0 | 11.1 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 19F | 8 (6.7) | 100 | 0 | 0 | 100 | 0 | 0 | 37.5 | 12.5 | 50 | 62.5 | 0 | 37.5 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 4 | 6 (5.0) | 100 | 0 | 0 | 100 | 0 | 0 | 83.3 | 0 | 16.7 | 66.7 | 16.7 | 16.7 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 19A | 5 (4.2) | 100 | 0 | 0 | 100 | 0 | 0 | 40 | 20 | 40 | 60 | 20 | 20 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| Sg18 | 5 (4.2) | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 3 | 4 (3.3) | 100 | 0 | 0 | 100 | 0 | 0 | 50 | 0 | 50 | 25 | 25 | 50 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 7F | 4 (3.3) | 100 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 100 | 50 | 0 | 50 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 8 | 3 (2.5) | 100 | 0 | 0 | 100 | 0 | 0 | 0 | 66.7 | 33.3 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 23F | 3 (2.5) | 100 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 35B | 3 (2.5) | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 12F | 2 (1.7) | 100 | 0 | 0 | 100 | 0 | 0 | 50 | 50 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 16F | 2 (1.7) | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 33F | 2 (1.7) | 100 | 0 | 0 | 100 | 0 | 0 | 0 | 100 | 100 | 50 | 0 | 50 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 8 | 1 (0.8) | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 17F | 1 (0.8) | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 38F | 1 (0.8) | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| NT |
3 (2.5) |
100 |
0 |
0 |
100 |
0 |
0 |
100 |
0 |
0 |
100 |
0 |
0 |
100 |
0 |
0 |
100 |
0 |
0 |
|||||
| Total |
120 |
98.3 |
1.7 |
0 |
100 |
0 |
0 |
38.3 |
17.5 |
44.2 |
68.3 |
5 |
26.7 |
98.3 |
1.7 |
0 |
100 |
0 |
0 |
|||||
| *S, susceptible; I, intermediate; R, resistant; NT, not serotyped. Boldface indicates pneumococcal conjugate valent 13 vaccine serotypes. Susceptibility testing and interpretation guidelines: penicillin MIC by Etest (S<2, I: 4, R>8 μg/mL); cefotaxime MIC by Etest (S<1, I 2, R>4 μg/mL); co-trimoxazole disk diffusion (S>19, I 16–18, R<15 mm); erythromycin disk diffusion (S>21, I 16–20, R<15 mm); ofloxacin disk diffusion (S>16, I 13–15, R<12 mm); vancomycin disk diffusion (>17 mm). | ||||||||||||||||||||||||
